Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2023
Apr. 30, 2022
Apr. 30, 2023
Apr. 30, 2022
Income Statement [Abstract]        
Revenue $ 210 $ 210
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 161 161
Research and development expenses (including non-cash stock-based compensation expenses of $492, $966, $998 and $2,243, respectively) 998 1,735 2,066 3,573
General and administrative expenses (including non-cash stock-based compensation expenses of $735, $779, $1,292 and $1,856, respectively) 1,611 1,854 3,099 3,896
Total operating costs and expenses 2,770 3,589 5,326 7,469
Loss from operations (2,560) (3,589) (5,116) (7,469)
Interest income 253 1 455 2
Net loss (2,307) (3,588) (4,661) (7,467)
Less: Net loss attributable to noncontrolling interest (19) (44) (51) (94)
Net loss attributable to common shareholders $ (2,288) $ (3,544) $ (4,610) $ (7,373)
Net loss per common share attributable to common shareholders:        
Basic and diluted $ (0.07) $ (0.12) $ (0.15) $ (0.24)
Weighted average common shares outstanding:        
Basic and diluted 30,930 30,152 30,924 30,138